The relationship between sodium glucose co-transporter 2 inhibitors and diabetic ketosis/infection: single center retrospective experiences
Ankyra Medical Journal · 2024
DOI: 10.51271/ankmj-0001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ankyra Medical Journal, 2024. Verfasst von Burak Tan und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Diabetes is a serious social problem in our country and around the world. Beyond hyperglycemia, it causes common and potentially life-threatening complications in all systems. For this reason, beyond the regulation of blood glucose, a holistic approach and combating complications are important in diabetes management. Sodium glucose co-transporter 2 inhibitors (SGLT2-i) are one of many antidiabetic drug families and stand out with their strong blood sugar regulation and cardiac and renal protective effects independent of blood sugar decrease. Despite its strong effectiveness, it is seen as risky in terms of diabetic ketosis and infection, which limits its use. We aimed to investigate the legitimacy of concerns by examining the relationship between SGLT-2 inhibitors and diabetic ketosis/infection.
Methods
Our study was designed single-center and retrospectively. 152 patients over the age of 18 who were treated as inpatients in our clinic with diabetic ketosis between January 2020 and June 2023 were included in the study. In these patients, ketosis and the severity of the infection clinic, if any, were examined through various parameters among Type 2 diabetic patients using SGLT-2 inhibitors, Type 2 diabetic patients not using SGLT-2 inhibitors, and Type 1 diabetes patients. These parameters were determined by the patient's blood and urine biochemistry tests at admission and discharge, the duration of ketosis treatment, the duration of intravenous antibiotic use, and the duration of hospitalization.
Results
Within the scope of the study, type 2 diabetic patients using SGLT-2 inhibitors were compared with type 2 diabetic patients not using SGLT-2 inhibitors and type 1 diabetic patients. In patients using SGLT-2 inhibitors, the leukocyte in urine, an indicator of urinary tract infection, was found to be significantly higher (p
Zitieren
APA
Tan, B., & Çifci, A. (2024). The relationship between sodium glucose co-transporter 2 inhibitors and diabetic ketosis/infection: single center retrospective experiences. Ankyra Medical Journal. https://doi.org/10.51271/ankmj-0001
Vancouver
Tan B, Çifci A. The relationship between sodium glucose co-transporter 2 inhibitors and diabetic ketosis/infection: single center retrospective experiences. Ankyra Medical Journal. 2024. doi:10.51271/ankmj-0001
BibTeX
@article{Tan2024,
author = {Tan, Burak and Çifci, Aydın},
title = {The relationship between sodium glucose co-transporter 2 inhibitors and diabetic ketosis/infection: single center retrospective experiences},
journal = {Ankyra Medical Journal},
year = {2024},
doi = {10.51271/ankmj-0001}
}
EUVIMED